Get the Stockscreener App
34.00
0.12%
0.04
After Hours:
34.00
Qiagen Nv stock is traded at $34.00, with a volume of 1.46M.
It is up +0.12% in the last 24 hours and down -17.13% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$33.96
Open:
$33.74
24h Volume:
1.46M
Relative Volume:
0.72
Market Cap:
$7.01B
Revenue:
$2.09B
Net Income/Loss:
$424.88M
P/E Ratio:
16.63
EPS:
2.0439
Net Cash Flow:
$447.20M
1W Performance:
-0.06%
1M Performance:
-17.13%
6M Performance:
-22.81%
1Y Performance:
-20.58%
1-Day Range:
$33.24
$34.09
1-Week Range:
$33.17
$34.84
52-Week Range:
$33.17
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
34.00 | 7.00B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN NV cuts FY outlook despite in-line prelim Q1 EPS - MSN
Qiagen NV expected to post earnings of 54 cents a shareEarnings Preview - TradingView
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Qiagen (QGEN) Is Down 10.8% After Cutting 2026 Sales Outlook Is The Bull Case Intact? - Sahm
QIAGEN NV Hits Day Low of $33.82 Amid Price Pressure - Markets Mojo
Primer: QIAGEN NV (QIA GY)May 2026 - Smartkarma
QIAGEN NV : Jefferies maintains a Buy rating - marketscreener.com
How The Qiagen (QGEN) Investment Story Is Shifting As Analysts Rework Their Assumptions - Yahoo Finance
Qiagen Trims 2026 Outlook After Mixed Q1 and QuantiFERON Weakness - TipRanks
Qiagen (NYSE:QGEN) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
QGEN Stock Price, Quote & Chart | QIAGEN N.V. (NYSE:QGEN) - ChartMill
QIAGEN N.V. (QGEN.US) will release its earnings report after the market closes on May 6. - Moomoo
Lower QuantiFERON demand leads QIAGEN (NYSE: QGEN) to trim 2026 outlook - Stock Titan
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $38 to $45 - Moomoo
MSN Money - MSN
Robert W. Baird Upgrades Qiagen (NYSE:QGEN) to Strong-Buy - MarketBeat
Morgan Stanley Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $39.69 - Moomoo
Qiagen Shares Plunge 10.7 Percent to Seven Year Low - HarianBasis.co
Pictet Asset Management Holding SA Reduces Holdings in Qiagen N.V. $QGEN - MarketBeat
Baird upgrades Qiagen NV (QGEN) - MSN
Qiagen Is Maintained at Overweight by JP Morgan - Moomoo
Barclays downgrades Qiagen NV (QGEN) - MSN
QGEN Maintained by JP Morgan -- Price Target Lowered to $45 - GuruFocus
QGEN Maintained by Citigroup -- Price Target Lowered to $38.00 - GuruFocus
JPMorgan Chase & Co. Has Lowered Expectations for Qiagen (NYSE:QGEN) Stock Price - MarketBeat
Citigroup Lowers Qiagen (NYSE:QGEN) Price Target to $38.00 - MarketBeat
QGEN Maintained by Barclays -- Price Target Lowered to $38.00 - GuruFocus
Citi Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $38 - Moomoo
QIAGEN NV Hits 52-Week Low at USD 33.82 Amidst Declining Performance - Markets Mojo
Morgan Stanley Cuts Price Target on QIAGEN to $40 From $51, Keeps Equalweight Rating - marketscreener.com
QGEN Upgraded by Baird -- Price Target Lowered to $43.00 - GuruFocus
Baird Upgrades QIAGEN to Outperform From Neutral, Cuts Price Target to $43 From $53 - marketscreener.com
Qiagen Sets Date for Publication of 2025 Annual Financial Report - The Globe and Mail
QIAGEN NV : DZ Bank gives a Buy rating - marketscreener.com
Qiagen (QGEN) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Qiagen (NYSE:QGEN) Sets New 12-Month LowShould You Sell? - MarketBeat
Qiagen N.V. (NYSE:QGEN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Qiagen NV (QGEN) Q1 2026 Earnings Call Highlights: Navigating Mi - GuruFocus
Baird upgrades Qiagen stock rating on valuation after pullback By Investing.com - Investing.com India
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $50 - Moomoo
Baird upgrades Qiagen stock rating on valuation after pullback - Investing.com
QIAGEN NV : Barclays reiterates its Neutral rating - marketscreener.com
Baird Upgrades Qiagen NV (QGEN) to Outperform - StreetInsider
Is Qiagen NV (QGEN) a Bargain After 10.7% Drop? GF Value Says Un - GuruFocus
Qiagen NV (QGEN) Falls to 7-Year Low as MidEast Tensions Drag Q1 - Yahoo Finance
Qiagen N.V. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Earnings Call Summary | Qiagen NV(QGEN.US) Q1 2026 Earnings Conference - Moomoo
QIAGEN NV : Jefferies keeps its Buy rating - marketscreener.com
Qiagen NV (QGEN) PT Lowered to $38 at Barclays - StreetInsider
Qiagen (NYSE:QGEN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
QIAGEN slides after cutting 2026 outlook, citing weaker QuantiFERON demand and cautious customer spending - Quiver Quantitative
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):